CytoDel, LLC has developed a technology that allows the Company to produce recombinant derivatives of botulinum neurotoxin (BTX) that creates molecular vehicles designed to safely deliver therapeutic (drug) payloads directly into nerve cells. This “Trojan Horse” type of approach enables active drugs to be delivered to high value targets that have previously been difficult or impossible to pursue because they are inside neurons. The Company has also discovered ways to improve pharmaceutical BTX products for musculoskeletal and aesthetic medicine.
CytoDel has participated in the NYU Venture Fellows program and started R&D operations at the Harlem Biospace, a biotechnology incubator. In order to fund operations, the Company recently completed its initial round of financing and was awarded a Phase I SBIR grant of approximately $225,000. The Company’s first SBIR grant is to study a recombinant botulinum neurotoxin for the treatment of neuromuscular disease and as potential safer alternative to products currently being used in aesthetic medicine.
This is the fifth post in the Startup Showcase series featuring video profiles of startups founded by NYU students, faculty and researchers.